Importantly, SkE was highly efficient at inhibiting chronic myelogenous leukemia (CML) cells that exhibit constitutive activation of the MAPK pathway and, accordingly, it impaired the phosphorylation of ERK1/2. This evidence concerns the gene MAPK3 and chronic myelogenous leukemia, BCR-ABL1 positive.